Composiciones, usos y métodos para el tratamiento de trastornos y enfermedades metabólicos

Un péptido quimérico que comprende o consiste en SEQ ID NO:2, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:69, o SEQ ID NO:70. The invention relates to a fusion of fibroblast growth factor 19 (FGF19) and fibroblast growth factor 21 (FGF21) and its use in the treatment of hyperglycemic condition, insulin re...

Full description

Saved in:
Bibliographic Details
Main Authors LINDHOUT, Darrin, LING, Lei
Format Patent
LanguageSpanish
Published 12.03.2020
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Un péptido quimérico que comprende o consiste en SEQ ID NO:2, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:69, o SEQ ID NO:70. The invention relates to a fusion of fibroblast growth factor 19 (FGF19) and fibroblast growth factor 21 (FGF21) and its use in the treatment of hyperglycemic condition, insulin resistance, hyperinsulinemia, glucose intolerance, metabolic syndrome, obesity, undesirable body mass, nonalcoholic fatty liver disease (NAFLD) nonalcoholic steatohepatitis (NASH), atherosclerosis and related disorders.
Bibliography:Application Number: ES20120807786T